Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Long-Term Deferred Tax (2020 - 2024)

Inmune Bio's Long-Term Deferred Tax history spans 4 years, with the latest figure at $25.7 million for Q4 2024.

  • For Q4 2024, Long-Term Deferred Tax rose 31.12% year-over-year to $25.7 million; the TTM value through Dec 2024 reached $25.7 million, up 31.12%, while the annual FY2024 figure was $25.7 million, 31.12% up from the prior year.
  • Long-Term Deferred Tax for Q4 2024 was $25.7 million at Inmune Bio, up from $545000.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $25.7 million in Q4 2024 and bottomed at $545000.0 in Q3 2024.
  • The 4-year median for Long-Term Deferred Tax is $8.6 million (2020), against an average of $10.6 million.
  • The largest annual shift saw Long-Term Deferred Tax soared 42.7% in 2023 before it surged 31.12% in 2024.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $3.5 million in 2020, then soared by 287.23% to $13.7 million in 2022, then skyrocketed by 42.7% to $19.6 million in 2023, then surged by 31.12% to $25.7 million in 2024.
  • Per Business Quant, the three most recent readings for INMB's Long-Term Deferred Tax are $25.7 million (Q4 2024), $545000.0 (Q3 2024), and $590000.0 (Q2 2024).